Overview

Pathophysiology of Cardiometabolic Risk Factors in African Americans

Status:
Completed
Trial end date:
2016-11-01
Target enrollment:
Participant gender:
Summary
The overall goal of this proposal is to determine the autonomic and nitric oxide contribution in the pathogenesis of hypertension and insulin resistance in obese African American women. For this purpose we will use two non-FDA approved drugs: Trimethaphan IND# 63826 Approval date 12/20/2001 L-NMMA IND# 41735 Approval date 09/1993
Phase:
Phase 1
Details
Lead Sponsor:
Vanderbilt University
Vanderbilt University Medical Center
Collaborator:
National Heart, Lung, and Blood Institute (NHLBI)
Treatments:
omega-N-Methylarginine
Trimethaphan
Trimethaphan camsylate